Hypereosinophilic syndrome presenting as peripheral neuropathy

D. Bell, I.G. Mackay and B. Pentland

University Department of Medicine, Royal Infirmary of Edinburgh and Astley Ainslie Hospital, Edinburgh, UK.

Summary: An unusual case of hypereosinophilic syndrome is described which presented with peripheral neuropathy with no evidence of cardiac involvement. The response to steroid therapy is documented and the literature on peripheral neuropathy in hypereosinophilic syndrome is reviewed.

Introduction

Hypereosinophilic syndrome (HES) is characterized by an increase in circulating eosinophils (greater than $1.5 \times 10^9/l$) for which there is no known cause. The central nervous system is affected in 30–50% of patients (Chusid et al., 1975; Spry et al., 1983a), and this usually consists of focal or diffuse cerebral involvement. There have been few reports of peripheral neuropathy in HES (Chusid et al., 1975; Dorfman et al., 1983) and none in which severe peripheral neuropathy was the presenting feature. We describe a patient with HES who presented with a peripheral neuropathy and review the literature on peripheral neuropathy in HES.

Case report

A 21 year old man presented in April 1983 with pain in his calves and forearms, paraesthesia of the hands and feet and impairment in handgrip of 4 weeks duration. He had general malaise and systemic enquiry revealed an episode of amaurosis fugax 3 weeks before admission. Fifteen months previously asthma had been diagnosed but this was well controlled on salbutamol and beclomethasone inhalers. There was no history of atopy, and skin tests to various allergens including aspergillus were negative apart from a positive reaction to house dust mite. At presentation he was pyrexial and looked unwell. Cardiovascular, respiratory and abdominal examination was normal. He had weakness and wasting of all the intrinsic muscles of the hands which was more marked on the left (Figure 1). There was weakness of elbow flexion and extension bilaterally with a severe left foot drop and slight distal weakness in the right leg. Sensation was impaired in a glove and stocking distribution with reduction of pinprick and light touch sensation to the level of wrists and ankles respectively. Knee, ankle and triceps jerks were absent, biceps and supinator reflexes were obtained with reinforcement and plantars were flexor. Fundoscopy was normal and there was no evidence of upper motor neurone involvement.

White cell count was $42.3 \times 10^9/l$ with $29.6 \times 10^9/l$ eosinophils, haemoglobin 14.5 g/dl, platelets $510 \times 10^9/l$ and ESR 95 mm/h. Bone marrow aspirate revealed large numbers of eosinophils and eosinophil precursors with a less marked increase in megakaryocytes and plasma cells. Chromosomal analysis was normal and leucocyte alkaline phosphatase score was elevated at 225.

Urinalysis and creatinine clearance were normal. Plasma alkaline phosphatase was elevated (199 IU/l) as was gamma-glutamyl transferase (205 IU/l). An isotope liver scan demonstrated moderate liver enlargement but laparoscopic liver biopsies were normal. Rose-Waaler differential factor was elevated on two occasions (1024 and 512 units) and there was a diffuse increase in immunoglobulins. Repeated urine, stool and blood cultures, were negative, as were stool microscopic examinations, screening for autoantibodies, complement and viruses, including hepatitis B surface antigen. Cerebrospinal fluid examination, electroencephalography, computed tomographic brain scan, chest X-rays, electrocardiogram, echocardiography, radionuclide ventriculography and abdominal aortography were also normal. Nerve conduction studies were performed on 3 occasions and no recordable potential could be obtained from the median nerves or the left ulnar nerve. The motor conduction velocity in the right ulnar nerve was significantly reduced on one occasion and at the lower end of the normal range on repeat testing. Sensory...
Figure 1 Photograph showing marked thenar, hypothenar and small muscle wasting in peripheral neuropathy, secondary to hypereosinophilic syndrome.

Table 1 Nerve conduction studies of right ulnar nerve

<table>
<thead>
<tr>
<th>Variable*</th>
<th>Normal values</th>
<th>15 May '83</th>
<th>5 Sept '83</th>
<th>13 Jan '84</th>
</tr>
</thead>
<tbody>
<tr>
<td>TL (ms)</td>
<td>2.1 - 3.4</td>
<td>2.4</td>
<td>3.3</td>
<td>3.1</td>
</tr>
<tr>
<td>MCV (m/s)</td>
<td>46.5 - 72.6</td>
<td>53</td>
<td>34</td>
<td>47.2</td>
</tr>
<tr>
<td>SCV (m/s)</td>
<td>38.5 - 65.2</td>
<td>unobtainable</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*TL = terminal latency at wrist; MCV = motor conduction velocity, elbow to wrist; SCV = sensory conduction velocity, finger to wrist.

potentials were obtained on the first occasion only. The results of right ulnar nerve conduction studies are given in Table I. Autonomic function studies were performed as described by Ewing & Clarke (1982) and these indicated parasympathetic damage. Sural nerve biopsy revealed perineural fibrosis and focal myelin degeneration but no inflammatory cell infiltrate or arteritic lesions.

One week after admission prednisolone therapy was started and his eosinophil count fell (Figure 2). During the first month his weakness increased, exercise tolerance declined and the painful paraesthesias persisted. In May, following laparoscopic liver biopsy, he had an episode of epigastric pain accompanied by a transient disturbance of liver enzymes which may have been related to enflurane anaesthesia. The following month he became anorexic, losing 18 kg in weight over a 3 month period, and his abdominal pain recurred. Despite an increase in his corticosteroid therapy his general condition deteriorated such that enteral nutri-

Figure 2 Total leucocyte and eosinophil count, and their response to steroid therapy in this patient with hypereosinophilic syndrome. (●) Total white cell count; (x) eosinophil count; NCV; nerve conduction velocities.
Discussion

This patient meets the diagnostic criteria for HES with persistent eosinophilia without demonstrable cause. This is a condition more common in males which usually presents between the third and sixth decades. In earlier reports of HES, peripheral neuropathy usually developed after cardiac or respiratory manifestation (Chusid et al., 1975; Dorfman et al., 1983). Five cases of peripheral neuropathy confirmed by nerve conduction studies have been described, the main features of which are summarized in Table II. Chusid et al. (1975), in their review of the literature, described four other cases; one of these had no neurological signs (Case Records, 1970), two had hyperreflexia and extensor plantars (Gardener-Thorpe et al., 1971; Yam et al., 1972) and the fourth had severe arterial disease (Novack et al., 1971). Our case would appear to be the first report of HES presenting with peripheral neuropathy, a feature which is an uncommon complication of the condition. Other features of HES, notably gastrointestinal involvement, subsequently developed in our patient. Of the five previously reported cases, three showed gradual improvement with corticosteroid therapy (Dorfman et al., 1983), whilst two (Chusid et al., 1975) had no response to corticosteroids or cyclophosphamide. While spontaneous improvement of the peripheral neuropathy may have occurred in our patient it seems more likely that corticosteroid therapy was of benefit in view of his eosinophil response.

The sural nerve biopsy showed no evidence of eosinophilic infiltration or arteritis in keeping with recent work which suggests that neural damage may be neurotoxic mediated. Eosinophils have been shown to contain neurotoxic substances responsible for the 'Gordon phenomenon' (Durack et al., 1979), a syndrome of muscular rigidity, ataxia and progressive paralysis, first described in laboratory animals following intraventricular injection of lymph node homogenates from patients with Hodgkin's disease (Gordon, 1933). Histologically, loss of Purkinje cells, vacuolation of the myelin sheath and axonal degeneration occurs, with peripheral nerve damage occasionally seen. Several eosinophil granule proteins have been purified and shown to reproduce the Gordon phenomenon. These include eosinophil-derived neurotoxin (Durack et al., 1981); eosinophil cationic protein and eosinophil protein X (Fredens et al., 1982). Eosinophil cationic protein also has specific toxic effects on the myocardial cell membrane (Spry et al., 1983b) and inhibits certain enzymes involved in mitochondrial respiration (Tai et al., 1982). We could detect no evidence of myocardial involvement in this case but it appears likely that the severe peripheral neuropathy may have been mediated by a circulating eosinophil neurotoxin.

Table II Summary of the previously reported cases of peripheral neuropathy in hypereosinophilic syndrome

<table>
<thead>
<tr>
<th>Reference</th>
<th>Age &amp; sex</th>
<th>Presenting features</th>
<th>Neurological findings</th>
<th>Neurological investigations*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chusid, M.J. et al. (1975)</td>
<td>42 M</td>
<td>Persistent cough, diaphoresis, rash, malaise, fatigue, fever</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chusid, M.J. et al. (1975)</td>
<td>39 M</td>
<td>Persistent cough, diaphoresis, rash, malaise, fatigue, fever</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dorfman, L.J. et al. (1983)</td>
<td>60 M</td>
<td>Diffuse pulmonary involvement, atrophy, coryza, rash</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dorfman, L.J. et al. (1983)</td>
<td>60 F</td>
<td>Diffuse pulmonary involvement, atrophy, coryza, rash</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dorfman, L.J. et al. (1983)</td>
<td>31 F</td>
<td>Asthma, atopy, rash</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*: decreased; NCV = nerve conduction velocities.
References